Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Grand View Research | PRODUCT CODE: 1841958

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1841958

U.S. Blood Testing Market Size, Share & Trends Analysis Report By Test Type, And Segment Forecasts, 2025 - 2033

PUBLISHED:
PAGES: 80 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

U.S. Blood Testing Market Summary

The U.S. blood testing market size was valued at USD 35.90 billion in 2024 and is projected to reach USD 71.41 billion by 2033, growing at a CAGR of 8.1% from 2025 to 2033. The market is primarily driven by the rising prevalence of chronic diseases such as diabetes, cardiovascular conditions, and cancer, which necessitate frequent diagnostic testing and monitoring for effective management.

Growing public awareness and a shift toward preventive healthcare, encouraging routine check-ups and early disease detection screening, are the major drivers for this market. In 2024, the Centers for Disease Control and Prevention (CDC) strengthened its core laboratory capabilities to detect and respond to high-priority pathogens. Recent technological innovations are a major catalyst for the market's expansion, improving the accessibility and efficiency of blood testing. For instance, in June 2024, the FDA granted marketing authorization for the first point-of-care Hepatitis C virus (HCV) RNA test, which enables single-visit testing and treatment using a fingertip blood sample.

Other key technological advances that are expected to impact this market are:

Artificial Intelligence Integration: AI and machine learning were pivotal in interpreting complex blood test data, enabling earlier disease detection, automation of smear analysis, improved biomarker identification, and reduced diagnostic errors. These systems accelerated result delivery and matched or exceeded clinical gold standards in sensitivity and specificity.

Lab-on-a-Chip Technology: Miniaturized devices capable of processing multiple blood tests on a single drop dramatically reduce laboratory demands, increasing access in remote and resource-limited regions while supporting rapid point-of-care diagnostics.

Wearable Biosensors: Smart devices (e.g., glucose and hemoglobin trackers) became possible for monitoring real-time, continuous blood composition. These are integrated with telemedicine platforms, improving chronic disease management, patient engagement, and rapid response to changes in health.

U.S. Blood Testing Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. blood testing market report based on test type:

  • Test Type Outlook (Revenue, USD Billion, 2021 - 2033)
    • Glucose Testing
    • A1C Testing
    • Direct LDL testing
    • Lipid panel testing
    • Prostate-specific antigen testing
    • COVID-19 testing
    • BUN testing
    • Vitamin D testing
    • Thyroid-stimulating hormone testing
    • Serum Nicotine / Cotinine testing
    • High sensitivity CRP testing
    • Testosterone testing
    • ALT testing
    • Cortisol testing
    • Creatinine testing
    • AST testing
    • Other blood tests
Product Code: GVR-4-68040-754-0

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test Type outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Blood Testing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Blood Testing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Blood Testing Market: Test Type Estimates & Trend Analysis

  • 4.1. Test Type Segment Dashboard
  • 4.2. U.S. Blood Testing Market: Test Type Movement Analysis
  • 4.3. U.S. Blood Testing Market Size & Trend Analysis, by Test Type, 2021 to 2033 (USD Billion)
  • 4.4. Glucose Testing
    • 4.4.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.5. A1C Testing
    • 4.5.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.6. Direct LDL testing
    • 4.6.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.7. Lipid Panel Testing
    • 4.7.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.8. Prostate-Specific Antigen Testing
    • 4.8.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.9. Covid-19 Testing
    • 4.9.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.10. BUN Testing
    • 4.10.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.11. Vitamin D Testing
    • 4.11.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.12. Thyroid-Stimulating Hormone Testing
    • 4.12.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.13. Serum Nicotine/Cotinine Testing
    • 4.13.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.14. High Sensitivity CRP Testing
    • 4.14.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.15. Testosterone Testing
    • 4.15.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.16. ALT Testing
    • 4.16.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.17. Cortisol Testing
    • 4.17.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.18. Creatinine Testing
    • 4.18.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.19. AST Testing
    • 4.19.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 4.20. Other Blood Tests
    • 4.20.1. Market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 5. Competitive Landscape

  • 5.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 5.2. Company/Competition Categorization
  • 5.3. Vendor Landscape
    • 5.3.1. Key company heat map analysis, 2024
  • 5.4. Company Profiles
    • 5.4.1. Abbott
      • 5.4.1.1. Company overview
      • 5.4.1.2. Financial performance
      • 5.4.1.3. Product benchmarking
      • 5.4.1.4. Strategic initiatives
    • 5.4.2. F. Hoffmann-La Roche Ltd
      • 5.4.2.1. Company overview
      • 5.4.2.2. Financial performance
      • 5.4.2.3. Product benchmarking
      • 5.4.2.4. Strategic initiatives
    • 5.4.3. Bio-Rad Laboratories, Inc.
      • 5.4.3.1. Company overview
      • 5.4.3.2. Financial performance
      • 5.4.3.3. Product benchmarking
      • 5.4.3.4. Strategic initiatives
    • 5.4.4. BIOMERIEUX
      • 5.4.4.1. Company overview
      • 5.4.4.2. Financial performance
      • 5.4.4.3. Product benchmarking
      • 5.4.4.4. Strategic initiatives
    • 5.4.5. Biomerica
      • 5.4.5.1. Company overview
      • 5.4.5.2. Financial performance
      • 5.4.5.3. Product benchmarking
      • 5.4.5.4. Strategic initiatives
    • 5.4.6. BD
      • 5.4.6.1. Company overview
      • 5.4.6.2. Financial performance
      • 5.4.6.3. Product benchmarking
      • 5.4.6.4. Strategic initiatives
    • 5.4.7. Quest Diagnostics Incorporated
      • 5.4.7.1. Company overview
      • 5.4.7.2. Financial performance
      • 5.4.7.3. Product benchmarking
      • 5.4.7.4. Strategic initiatives
    • 5.4.8. Siemens Healthineers AG
      • 5.4.8.1. Company overview
      • 5.4.8.2. Financial performance
      • 5.4.8.3. Product benchmarking
      • 5.4.8.4. Strategic initiatives
    • 5.4.9. Danaher Corporation
      • 5.4.9.1. Company overview
      • 5.4.9.2. Financial performance
      • 5.4.9.3. Product benchmarking
      • 5.4.9.4. Strategic initiatives
    • 5.4.10. Trinity Biotech Plc
      • 5.4.10.1. Company overview
      • 5.4.10.2. Financial performance
      • 5.4.10.3. Product benchmarking
      • 5.4.10.4. Strategic initiatives
Product Code: GVR-4-68040-754-0

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. blood testing market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Table 3 U.S. blood testing market, by test type, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. blood testing market: market outlook
  • Fig. 10 Blood testing competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. blood testing market driver impact
  • Fig. 16 U.S. blood testing market restraint impact
  • Fig. 17 U.S. blood testing market strategic initiatives analysis
  • Fig. 18 U.S. blood testing market: Test type movement analysis
  • Fig. 19 U.S. blood testing market: Test type outlook and key takeaways
  • Fig. 20 Glucose testing market estimates and forecast, 2021 - 2033
  • Fig. 21 A1C testing market estimates and forecast, 2021 - 2033
  • Fig. 22 Direct LDL testing market estimates and forecast, 2021 - 2033
  • Fig. 23 Lipid panel testing market estimates and forecast, 2021 - 2033
  • Fig. 24 Prostate-specific antigen testing market estimates and forecast, 2021 - 2033
  • Fig. 25 COVID-19 testing market estimates and forecast, 2021 - 2033
  • Fig. 26 BUN testing market estimates and forecast, 2021 - 2033
  • Fig. 27 Vitamin D testing market estimates and forecast, 2021 - 2033
  • Fig. 28 Thyroid-stimulating hormone (TSH) market estimates and forecast, 2021 - 2033
  • Fig. 29 Serum nicotine/cotinine market estimates and forecast, 2021 - 2033
  • Fig. 30 High sensitivity CRP testing market estimates and forecast, 2021 - 2033
  • Fig. 31 Testosterone testing market estimates and forecast, 2021 - 2033
  • Fig. 32 ALT testing market estimates and forecast, 2021 - 2033
  • Fig. 33 Cortisol testing market estimates and forecast, 2021 - 2033
  • Fig. 34 Creatinine testing market estimates and forecast, 2021 - 2033
  • Fig. 35 AST testing market estimates and forecast, 2021 - 2033
  • Fig. 36 Other blood tests market estimates and forecast, 2021 - 2033
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!